Table 3.

Summary of new HIV-specific T cell responses on study. Two definitions of a new response were used. In definition 1, subjects were considered responders if they had any post-vaccination cultured ELISPOT titer that was >1 log₁₀ above the log₁₀ ELISPOT response at baseline, regardless of study arm. In definition 2, a response was an area under the response curve (AUC) to a given peptide antigen pool that was greater than the maximum AUC to the same stimulant observed in the placebo arm. Because the latter definition was intended to account only for those responses that exceeded the greatest background responses seen in the absence of DermaVir exposure, this meant that subjects in the placebo group could not be classified as responders under this approach. Similarly, this definition required no missing data up the 37-week timepoint. Data are shown as number (percent) of responders per group

	Peptide pool
	Gag p17	Gag p24	Gag p15	Tat-Rev	Any peptide pool	P-value
Responder definition 1
Study group
Placebo (N =5)	1 (20)	1 (20)	1 (20)	4 (80)	4 (80)
Low-dose (N = 5)	2 (40)	3 (60)	2 (40)	1 (20)	4 (80)	1*
Intermediate-dose (N = 5)	2 (40)	2 (40)	1 (20)	3 (60)	4 (80)	1*
High-dose (N = 6)	3 (50)	2 (33.3)	2 (33.3)	1 (16.7)	3 (50)	0.545*
Combined DermaVir (N = 16)	7 (43.8)	7 (43.8)	5 (31.3)	5 (31.3)	11 (68.8)	1*
Responder definition 2
Study group
Low-dose (N = 3)	2 (66.7)	3 (100)	2 (66.7)	1 (33.3)	3 (100)	0.167**
Intermediate-dose (N = 4)	2 (50)	4 (100)	4 (100)	4 (100)	4 (100)	0.076**
High-dose (N = 6)	2 (33.3)	1 (16.7)	1 (16.7)	1 (16.7)	2 (33.3)
Combined DermaVir (N = 13)	6 (46.2)	8 (61.5)	7 (53.8)	6 (46.2)	9 (69.2)

^*Comparing each group to the placebo group, Fisher’s exact test

^**Comparing to the high-dose group, Fisher’s exact test. P value is not defined for the comparison of the low- and intermediate-dose groups (both 100%).